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SF3B1 mutant MDS-initiating cells may arise from
the haematopoietic stem cell compartment
Syed A. Mian1,*, Kevin Rouault-Pierre2,*, Alexander E. Smith1,3, Thomas Seidl1, Irene Pizzitola2, Aytug Kizilors3,
Austin G. Kulasekararaj1,3, Dominique Bonnet2 & Ghulam J. Mufti1,3
Despite the recent evidence of the existence of myelodysplastic syndrome (MDS) stem cells
in 5q-MDS patients, it is unclear whether haematopoietic stem cells (HSCs) could also be the
initiating cells in other MDS subgroups. Here we demonstrate that SF3B1 mutation(s) in our
cohort of MDS patients with ring sideroblasts can arise from CD34þCD38CD45RA
CD90þCD49fþ HSCs and is an initiating event in disease pathogenesis. Xenotransplanta-
tion of SF3B1 mutant HSCs leads to persistent long-term engraftment restricted to myeloid
lineage. Moreover, genetically diverse evolving subclones of mutant SF3B1 exist in mice,
indicating a branching multi-clonal as well as ancestral evolutionary paradigm. Subclonal
evolution in mice is also seen in the clinical evolution in patients. Sequential sample analysis
shows clonal evolution and selection of the malignant driving clone leading to AML trans-
formation. In conclusion, our data show SF3B1mutations can propagate from HSCs to myeloid
progeny, therefore providing a therapeutic target.
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M
yelodysplastic syndromes (MDS) are clonal haemato-
poietic disorders with diverse phenotypes, characterized
by varying severity of ineffective haematopoiesis, bone
marrow (BM) dysplasia, variable rates of progression to acute
myeloid leukaemia (AML), overall survival and response to
therapy1,2. Recent studies have implicated defects of pre-
messenger RNA splicing gene SF3B1 in the pathogenesis of
MDS patients with ring sideroblasts (MDS-RS). SF3B1 mutations
are present in up to 80% of the MDS-RS patients3–5 and strongly
correlate with the presence of ringed sideroblasts4–7. It is
noteworthy that all the mutations reported thus far in SF3B1
gene are heterozygous3–5,8, and knockout homozygous mouse
models are embryonically lethal9.
Over the years, it has been reported that self-renewing
haematopoietic stem cells (HSCs) continuously acquire somatic
aberrations, while most of them are passenger mutations, some
‘potent mutations’ can constitute a reservoir of pre-leukaemic
stem cells10–12. The ﬁrst study to report clonal spectrum at a
single-cell level through multiplex ﬂuorescence in situ
hybridization (FISH) analysis was in childhood acute
lymphoblastic leukaemia13. However, the recent developments
of genomic technologies, stem cell isolation as well as
xenotransplantation models has started to lead to a better
understanding of the complex clonal architecture and mutational
hierarchy of phenotypically and functionally deﬁned ‘malignant
stem cells’ in AML14. A recent study on del(5q) MDS patients
provided the ﬁrst evidence of the genetic evolution and
phenotypic hierarchy in del(5q) MDS before AML
transformation15.
In MDS-RS patients, the landscape of somatic mutations has
become increasingly well deﬁned3–5,7,16. However, the speciﬁc
step within the developmental schema at which a clone attains a
particular genetic aberration necessary to emerge or re-emerge as
a dominant clone remains unknown. For instance, we have
previously shown that the sequential acquisition of oncogenic
alterations (such as FLT3 and RUNX1) in SF3B1 mutant MDS-RS
patients results in disease progression to AML4. However, the
origin of SF3B1 mutations, the detailed clonal composition
(single-cell level), evolution as well as the engraftment kinetics of
the haematopoietic cells that carry the SF3B1 mutations remain
unknown. Therefore, we hypothesized that SF3B1 mutations play
a central role in MDS-RS pathogenesis, can arise from the more
immature HSCs and hence provide a genetic marker to study the
clonal evolution from the MDS disease to leukaemic
transformation.
Our data demonstrate that SF3B1 mutations in MDS-RS
patients can originate in rare HSCs and precede other known
genetic lesions. Using xenotransplantation assays, we show that
SF3B1 mutant clone alone or in association with other lesions
confer clonal growth advantage over ‘normal’ cohabitating cells in
NOD/SCID/IL2rg / (NSG) mice. In addition, the xenograft
NSG model recapitulates the clonal changes occurring in patients’
bone marrow (BM). Furthermore, the fact that SF3B1-mutated
stem cells constitute a ‘pre-leukaemic’ reservoir for more
destabilizing mutations to occur points to the need of further
large in vivo studies to identify, monitor and develop effective
therapeutic strategies to prevent further subclonal evolution,
recurrence and disease progression observed in MDS-RS patients.
Results
SF3B1 mutations arise in HSC and persist in myeloid progeny.
Whole-exome sequencing (WES) of CD34þ cells from a cohort
of 12 MDS-RS (8 RARS, 1 RCMD-RS, 2 RARS-T and 1 tMDS;
Supplementary Table 1) including 8 previously reported4 and 1
congenital sideroblastic anaemia patient, revealed acquired
mutations in SF3B1 in 11/13 cases (Supplementary Tables 1
and 2, Supplementary Fig. 1). A constitutional ALAS2 (R425C)
gene mutation17–19 was detected in the patient with congenital
sideroblastic anaemia, but no other mutations including SF3B1
(Supplementary Table 2) were observed in this case. Previous
published studies have reported that recurrent gene mutations
such as TET2, DNMT3A and JAK2 coexist in patients with
SF3B1 mutations at variable frequencies (Supplementary
Table 3)4,8,20,21. In our cohort of 12 MDS-RS patients, SF3B1/
DNMT3A, SF3B1/TET2, SF3B1/JAK2 coexisted in 6, 2 and 1
patient, respectively. Using WES data, we were able to use the
mutant allele burden (MAB) as a mean for predicting the
hierarchy of the mutations. In 2/6 cases where DNMT3A and
SF3B1 mutations coexist, SF3B1 mutation was present as a
dominant clone (Supplementary Fig. 1, MDS1 and -6). In 3/6
patients, SF3B1 and DNMT3A mutations had similar MABs
(MDS2, -10 and -12). In only one patient, DNMT3A (MDS11)
had a DNMT3A clone higher than SF3B1 (70 versus 60%,
respectively).
Nevertheless, for TET2, and JAK2, where MABs between SF3B1
and these mutations were similar, it was not possible to decipher
which mutation was ancestral without further clonal analysis.
Unfortunately, for MDS10, MDS11 and 12, no viable BM cells
were available to further dissect the clonal composition.
Here, we used 5 out of 12 MDS-RS patients, one congenital
sideroblastic anaemia and three haematologically normal controls
for further in vitro and in vivo analysis (Supplementary Table 4).
An additional MDS-RS patient (n¼ 1; MDS14) with SF3B1
mutation H662Q was also included in this study (Supplementary
Table 1).
To identify the target cell within the haematopoietic compart-
ment, which carries the SF3B1 mutation, HSCs, multipotent
progenitors (MPPs), granulocyte macrophage progenitors
(GMPs) and megakaryocyte erythrocyte progenitors (MEPs)
were isolated from the BM of four patients (MDS1, MDS2,
MDS4 and MDS6) harbouring SF3B1 mutation (Supplementary
Fig. 2A,B; Supplementary Table 1). To date, HSC in MDS studies
have been enriched with the following markers LinCD34þ
CD38CD90þCD45RA (ref. 22). To increase the HSCs
purity, CD49f (integrin alpha 6) was used along with
LinCD34þCD38CD90þCD45RA , which allowed us to
enrich our population in long-term HSCs23. We performed
targeted mutational analysis on the ﬂuorescence-activated cell
sorting (FACS)-puriﬁed cells from all patients and showed that
SF3B1 mutations originate in the rare HSC population (Fig. 1).
SF3B1 mutations were detected in the MPPs, GMPs and MEPs
fractions in all patients (Fig. 1). Notably, the MAB was largely
maintained between the HSCs, MPPs and more differentiated
myeloid progenitors.
WES data from three of the patients (MDS1, MDS2 and
MDS4) identiﬁed additional patient-speciﬁc mutations in
CD34þ cells. Next, we sought to determine whether these
patient-speciﬁc mutations originate from the same HSC malig-
nant pool as SF3B1 or whether they occur downstream of the
stem cell differentiation in MPPs, GMPs and MEPs. Mutational
analysis demonstrated that the majority of the patient-speciﬁc
mutations including clinically important myeloid-speciﬁc genes
such as DNMT3A and JAK2 were present in the rare HSC
population and in the mature myeloid progenitors, that is, MPPs,
GMPs and MEPs (Fig. 2). We also observed in some cases that
‘patient-speciﬁc mutations’ are either gained or lost at the mature
progenitor level. This could be due to the fact that these
mutations are present as minor clones (o10% MAB) and are as
such diluted further. None of the gene mutations including SF3B1
were detected in the mesenchymal stromal cells cultured from the
patient’s BM samples (data not shown). Furthermore, we and
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others have previously shown that SF3B1 mutations are not
detected in T- or B cells in MDS-RS patients4,5. Taken together,
in our cohort of patients SF3B1mutations are clonally propagated
by HSCs to their mature myeloid progenitors, but not to the
lymphoid progenitors.
MDS-ICs are restricted to the rare HSC fraction. The NSG mice
models in which primary human leukaemic cells are transplanted
have previously been used to expand our understanding of the
pathogenesis of human leukaemia13,24. Although MDS patient
cells are difﬁcult to engraft in xenograft models, the recent use of
NSG mice as well as intra-bone injection (with or without co-
injection of mesenchymal stroma cells) have been reported to
yield higher engraftment15,22,25. Therefore, we prepared CD34þ
BM cells from four SF3B1-mutated MDS-RS patients (MDS1,
TP1; MDS2, TP1; MDS3; MDS4) and one congenital sideroblastic
anaemia patient (MDS5 with ALAS1 mutation), which was used
as a control. Following on, these cells were then transplanted into
NSG mice (Fig. 3a; Supplementary Table 4). In parallel, we
injected adult BM CD34þ cells from three healthy donors into
NSG mice to control any lineage bias.
Engraftment levels based on human CD45þ cells harvested
from engrafted mice at week 18–20 ranged between 0.1 and 4.9%
(Fig. 3b; Supplementary Table 4). Majority of the cells engrafted
in mice were of myeloid lineage with little or no lymphoid cell
engraftment. In contrast, mice injected with CD34þ cells from a
congenital sideroblastic anaemia patient showed myeloid as well
as lymphoid cell engraftment (Fig. 3c; Supplementary Table 4).
Similarly, engraftment observed in mice transplanted with
CD34þ cells from normal healthy controls exhibited a higher
ratio of lymphoid/myeloid cell as compared with SF3B1 mutant
cases (Fig. 3c). It is important to emphasize that B cells in MDS-
RS patients do not carry the SF3B1 mutation4. Therefore, data
from our study suggest that the presence of SF3B1 mutations,
perhaps along with additional ‘cooperating factors’, adversely
affects the lymphoid cell development in this model, which is in
agreement with the previous xenotransplantation models
proposed15,22.
To conﬁrm the nature of the human engrafted CD45þCD33þ
cells (HECs) recovered from mice, mutational analysis was
performed on HECs (Supplementary Table 5). Interestingly, the
genotypic characteristics of patients’ primary CD34þ BM cells
were maintained in HEC, as demonstrated by the presence of
SF3B1 mutations. As mentioned above, SF3B1 mutations are
heterozygous ones, therefore a MAB of 50% implies that 100% of
the cells carry the mutation. SF3B1 MAB remained largely
unchanged between the primary CD34þ cells (E43%), and
post-transplant HEC (E46%) in 3/4 cases (Fig. 3d). This was
irrespective of the type of SF3B1 mutations (K700E, n¼ 2;
H662Q, n¼ 2). In one RARS patient (MDS3), SF3B1 (K700E)
MAB increased from 28% in primary CD34þ cells to 43%
(average MAB between three mice) after xenograft transplanta-
tion. SF3B1 mutations were also observed in cells cultured in
both CFC and long-term culture (LTC) conditions, at a variable
MAB frequency (Fig. 2; Supplementary Fig. 5). Therefore,
our data suggest a clonal advantage of the malignant mutant
clone(s) over cohabitating normal HSCs in SF3B1 mutant
MDS-RS cases.
Finally, we sought to determine which progenitor cells within
the haematopoietic compartment were able to engraft in NSG
mice. To address this, we isolated HSC, MPP, MLP, CMP
and GMP from one MDS-RS patient (MDS14) with SF3B1
H662Q mutation and injected each fraction separately into
mice. Interestingly, the mouse that received SF3B1-mutated
HSCs engrafted and the SF3B1 H662Q MAB in mice was
maintained (Table 1), which is similar to the recent data from
Woll et al.15
Xenograft exhibits subclonal evolution of SF3B1 mutant clones.
To further explore the clonal landscape and evolution of the
SF3B1 mutant cells in our xenograft, we performed WES and/or
targeted mutational analysis on the HECs. This strategy enabled
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us to reliably trace SF3B1 and coexisting mutations as well as
to detect de novo gene mutations. All the mutations were
conﬁrmed in at least one non-whole-genome ampliﬁed (WGA)
HEC sample in all cases (see Methods for more details). The
degree of quantitative accuracy of the allele burdens for WGA
DNA was validated independently (Supplementary Fig. 3A,B; see
Methods for details).
NSG xenograft maintained (or enhanced) the malignant SF3B1
clone in general; however, the subclonal population shift traced
via the changes in the MABs was observed in 2/4 cases (Fig. 2;
Supplementary Fig. 5; Supplementary Table 5). For example, in
MDS1, JAK2 (V617F) MAB decreased from 36–15% (average
MAB for three mice; Fig. 2; Supplementary Fig. 5), whereas the
DNMT3A increased to 10%. A similar trend was observed for
other gene mutations in this patient. Interestingly, DNMT3A
mutation was not initially detected in primary CD34þ cells by
WES. However, a follow-up high-depth targeted mutational
analysis conﬁrmed the presence of these mutations at a low level
(o5%) in the primary CD34þ cells (Fig. 2; Supplementary
Fig. 5). On the other hand, TLL2 mutation present in the MDS2
(7% MAB) CD34þ cells almost disappeared in the NSG mice
(1% MAB, Fig. 2). In the rest of the cases, patient-speciﬁc
mutations followed the same trend as SF3B1 clones, implying the
presence of a single SF3B1 clone with multiple mutations. In all
cases, similar clonal/subclonal changes were observed in pooled
CFC and LTC assays.
Together our data demonstrate that SF3B1malignant cells were
maintained or even enhanced in NSG mice and that subclonal
ﬂuctuation could be detected in certain cases. Of note, all the
mutations present in the NSG mice were traced back to the
patients’ primary CD34þ cells and no new mutations were
detected in the NSG mice.
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Figure 2 | Mutational architecture and subclonal evolution of SF3B1-mutated MDS-RS bone marrow cells. Panels show the gene mutations with their
MABs in primary CD34þ bone marrow, HEC cells and LTC samples from each patient. Outer red circle represents the total SF3B1 clone and the inner
sections of the circle represents the SF3B1 subclones. MABs for HEC samples are the average of all mouse samples (where applicable, that is,41 mouse).
Percentages displayed in the pie chart indicate the MAB frequency modulation in HEC and LTC samples versus CD34þ day 0. *Po0.01% (t-test) for
difference in SF3B1 MAB frequency between CD34þ day 0 and HEC and/or LTC samples for the MDS3 sample. For more details about statistical analysis
of the variation in MAB frequencies, refer to Supplementary Fig. 5. The table on the right side of each panel represents the mutation status of the respective
genes in the HSC, MPP, GMP and MEP cell populations for each patient. Samples used to isolate cell fractions (HSCs, MPPs, GMPs and MEPs) were taken
B18 months later than the ﬁrst sample used to isolate CD34þ cells. Three independent PCRs were performed to conﬁrm/determine the MAB throughout
the experiments. In the tables on the right side, the black boxes indicate that MAB for gene mutations was the same as the primary CD34þ cells, dark grey
boxes show MAB for gene mutations that wasr2-fold as compared to the primary CD34þ cells, light grey boxes represent MAB for gene mutations that
wasZ2-fold as compared with the primary CD34þ cells and pink boxes indicate not detected or below background noise level. MAB mutant allele burden;
HEC, human engrafted cell; LTC, long-term culture; BM, bone marrow; Mut, mutation.
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Clonal analysis reveals mutational architecture in MDS-RS.
Previous studies have described mutational landscape of SF3B1-
mutated patient BM cells3–5,8. However, these studies have
inferred the clonal architecture in the total BM samples through
the identiﬁcation of clusters of coexisting mutations with similar
MABs, and this does not necessarily recapitulate the actual
subclonal architecture of the patients’ BM compartment.
Therefore, to gain insight into the clonal landscape of
coexisting mutations in SF3B1 mutant MDS-RS patients, we
performed a single-cell clonogenic assay using CD34þ cells from
four patients (MDS1, time point 1; MDS2, TP1; MDS3; MDS4),
followed by targeted mutational analysis of the patient-speciﬁc
mutations.
Initial mutational analysis performed on individual CFC
colonies from MDS1 (48–96 colonies), MDS2 (47 colonies),
MDS3 (46 colonies) and MDS4 (30 colonies) using gene-speciﬁc
primers targeting SF3B1 mutations revealed that 97%, 98%, 96%
and 77% of the colonies carried SF3B1 mutant gene, respectively
(Fig. 4; Supplementary Fig. 6). Moreover, further analysis of the
‘patient-speciﬁc’ gene mutations in these cases revealed the
complex heterogeneity within the SF3B1-mutated colonies. For
example, MDS1 and MDS2 had a marked subclonal heterogeneity
(Fig. 4). Notably, driver mutations such as DNMT3A were present
in 44/47 MDS2 colonies, suggesting that it may have been
acquired at a later time point during disease progression. MDS1
demonstrated six different SF3B1 subclones where 15/48 colonies
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Figure 3 | Engraftment and genotype of human RARS-originated and control haematopoietic cells in the bone marrow of NOD/SCID/IL2rc/ mice.
(a) Schematic representation of the xenograft model. Right-hand side panel shows the ﬂow cytometry proﬁle of bone marrow cells recovered from one
human-cell-engrafted mice. The majority of human CD45-expressing cells were positive for a myeloid marker CD33þ in all analysed cases in this study.
(b) Percentage of human CD45þ cells in the bone marrow of NSG mice at 6 and 18–20 weeks after transplantation (MDS1, n¼ 3; MDS2, n¼ 1; MDS3,
n¼ 3 and MDS4, n¼ 1). (c) Percentages of human haematopoietic cells and ratio of CD19þ/CD33þ isolated from the bone marrow of mice engrafted with
either MDS-RS (n¼4 patients and transplanted in a total eight mice) or healthy controls CD34þ cells (n¼ 3 healthy donors and transplanted in a total of
11 mice) or congenital sideroblastic anaemia patient (n¼ 1 patient transplanted in two mice). The y axis (left) represents the percentage of the human
CD45þ cells present in the total mouse bone marrow. The y axis (right) represents the ratio of the human CD19þ versus human CD33þ cells within the
human CD45þ cells recovered following xenotransplant. MDS xenografts showed a signiﬁcant skewing towards myeloid lineage. *Po0.05, ****Po0.0001
(t-test). (d) Targeted mutational analysis shows the presence of concordant SF3B1mutations in primary CD34þ bone marrow sample (grey) and xenograft
(black) in all analysed cases. Three independent PCR/sequencing experiments were performed to conﬁrm/determine the mutant allele burden throughout
the experiments. The sequencing coverage across the SF3B1 amplicons was Z1,000 reads. *Po0.01 (t-test).
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Table 1 | Engraftment of sorted haematopoietic cells in NSG.
SF3B1 mutation
CD34þ cells
Mouse
model
Cells
injected
Engrafted
mice
hCD33% cells
hCD19% cells
(12 weeks)
SF3B1MAB in
CD34þ cells
(day 0)
SF3B1MAB in HEC
(12 weeks)
LinCD45þCD34þCD38
HSC
CD45RACD90þCD49fþ
H662Q NSG 1,629 1/1 100%
0.00%
46% 46%
MPP
CD45RACD90CD49f
H662Q NSG 29,944 0/1 NA NA NA
LinCD45þCD34þCD38
MLP
CD45RAþCD90
H662Q NSG 51 0/1 NA NA NA
CMP
CD45RACD135þ
H662Q NSG 16,231 0/1 NA NA NA
GMP
CD45RAþCD135þ
H662Q NSG 28,217 0/1 NA NA NA
FACS, ﬂuorescence-activated cell sorting; GMP, granulocyte macrophage progenitor; HEC, human engrafted CD45þCD33þ cell; HSC, haematopoietic stem cell; MAB, mutant allele burden; MDS,
myelodysplastic syndrome; MDS-IC, MDS-initiating cell; MDS-RS, MDS patients with ring sideroblast; MPP, multipotent progenitor; NA, not applicable; NSG, NOD/SCID/IL2rgOD mice.
The table shows the engraftment of FACS-isolated haematopoietic cell fractions injected into NSG mice. Progenitor cells from one MDS-RS patient were isolated and injected separately into NSG mice. After 12
weeks, mice were killed and the bone marrow was analysed. Only the rare HSC fraction gave rise to a myeloid-restricted engraftment, indicating the nature of the MDS-ICs in this rare HSC fraction.
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had SF3B1 mutations alone (Fig. 4; Supplementary Fig. 6).
Interestingly, some of these subclones were mutually exclusive,
especially subclones with known driver mutant genes such as
JAK2 and DNMT3A, therefore representing a branching
multi-clonal evolution (Fig. 4). In contrast, the simplest of the
genetic architectures was present in MDS3 and MDS4 where only
two and three mutant SF3B1 subclones were observed, respec-
tively (Fig. 4).
It is noteworthy that CFC individual colonies with wild-type
SF3B1 (MDS1, n¼ 2; MDS2, n¼ 1; MDS3, n¼ 2 and MDS4,
n¼ 7) had no additional gene mutations among those screened
(Fig. 4; Supplementary Fig. 6). We therefore provide further
evidence that SF3B1 mutations are present in the majority of the
CD34þ cells and, importantly, precede other driver mutations
such as DNMT3A and JAK2 as evidenced here. This implies that
SF3B1 mutation is the ‘founder mutation’ in these MDS-RS
patients.
Xenograft recapitulates the clonal evolution in patients BM. To
ascertain whether the xenograft clonal changes observed, occur in
the MDS-RS patient BM, we performed targeted mutational
screening on sequential samples (total nucleated cells) obtained
from two patients (MDS1, E18 months after initial sampling
with no clinical disease progression, TP2; MDS2, E29 months
after the ﬁrst sampling at the AML transformation stage, TP2;
Supplementary Table 1). SF3B1 mutations were largely unchan-
ged between the two time points in both patients (Fig. 5;
Supplementary Fig. 7). However, in MDS1, a change in the MAB
of additional somatic mutations was observed in the sequential
sample (TP2; Supplementary Fig. 7). For example, JAK2 subclone
(V617F, 36–13%) diminished (Fig. 5), whereas DNMT3A clone
increased from 4–15%, in the sequential sample (TP2, Fig. 5).
Strikingly, cells from TP1 engrafted into the mice and harvested at
week 20, demonstrated similar subclonal changes as observed in
the sequential patient TP2 (Fig. 5). These data along with our
clonogenic data suggest that four SF3B1 subclones exist in this
patient; however, ‘isolated SF3B1’ and ‘SF3B1 plus DNMT3A’
clones have a growth advantage over ‘SF3B1-JAK2’ clone and
others in NSG mice as well as in the human BM environment
(TP2).
In MDS2, CCDC17 and TLL2 mutations were not detected in
the sequential sample while the rest of the mutations were largely
maintained. A similar trend was observed in the NSG mice where
TLL2 gene mutation diminished to 1% in the HEC sample
(Supplementary Fig. 7). Altogether, our data suggest that the
xenograft model does recapitulate some of the clonal changes
occurring in the patients’ BM in one case, while as in another case
where AML transformation occurred, a partial recapitulation was
observed. This could be probably due to the stochastic acquisition
of additional genomic lesion at the later stage of the disease.
Meanwhile, it is noteworthy that the ‘incubation period’ of the
MDS BM cells in NSG mice was only 20 weeks while the patient
(MDS2) transformed to AML 29 months after the ﬁrst MDS
sampling.
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Sequential lesions in SF3B1 clones leads to transformation.
MDS2 patient evolved into AML 29 months after the ﬁrst MDS
sample was taken (MDS2, TP1). It is important to note that
leukaemic transformation in RARS disease is a very rare event.
Initially, we performed FACS analysis on BM samples (TP3) to
examine the phenotypic changes that could have occurred in the
BM leading to AML (Fig. 6a). The frequency of CD34þ cells in
BM mononuclear cells (MNCs) at AML stage (at 29 months) was
signiﬁcantly higher as compared with the MDS stage 35.3 and
1.54%, respectively. Interestingly, a remarkable shift of cell
populations was observed within the CD34þCD38 and
CD34þCD38þ compartments showing a marked increase in
MLPs (499%) and GMPs (499%) at the AML stage (TP3)
(Fig. 6a). If this result implies the switch from a stem cell disease
to a progenitor disease, where a MDS progenitor would have
acquired self-renewal ability and became AML blast, we should be
able to identify MDS-initiating cells (MDS-ICs) still present at the
AML stage. Thus, we sought to investigate the contribution of
additional genomic lesions (chromosomal aberrations; gene
mutations, known ‘driver’ or ‘passenger’ mutations) acquired at
the AML stage. Metaphase cytogenetics at the AML stage revealed
complex chromosomal changes (Supplementary Table 1)
including del(7q). To understand whether del(7q) was a
major event in the transformation process, we traced back this
chromosomal aberration by FISH analysis (Supplementary
Fig. 8A) of the whole BM sample, MLPs and GMPs at the
AML stage and also on the whole BM sample at the MDS stage
(TP1). Two chromosome-7 aberrations were detected at the AML
stage of the disease with 93% harbouring del (7q36) and 7%
containing del(7q22-7q36), in the total MNCs, in the MLPs and
in the GMPs (Fig. 6b,c). Interestingly, only del(7q36) was
traced back to the MDS stage of the disease; however, the
frequency was signiﬁcantly lower, that is, 2% (Fig. 6d,e). We
were unable to perform FISH analysis on the phenotypically
deﬁned HSCs, MPPs, CMPs and MEPs due to the low
frequency of these progenitors in the BM at the AML stage. It is
noteworthy that FISH analysis on the LTC-derived cells (MDS
stage TP1) showed low-level del(7q36) clone (3%; Fig. 6d),
therefore suggesting that the major clone containing del(7q36)
is an early lesion acquired in the SF3B1 mutant rare HSCs at an
MDS stage of the disease. However, SNV proﬁle through WES
on LTC showed no change in the loss of heterozygosity at
chromosome 7, and similar results were observed at the MDS
stage for CD34þ cells, HEC (MDS stage) and CD3þ cells
(Supplementary Fig. 8B).
As the del(7q) does not seem to be a ‘marker’ of the AML
transformation, we sought for other targets through WES. Results
showed that SF3B1 and other additional gene mutations
including DNMT3A were maintained; however, CCDC17 and
TLL2 were not detected (Fig. 6f). Further analysis revealed
additional patient-speciﬁc mutations, including SUV420H1
(L645F) novel mutation (Fig. 6f), which is a histone methyl-
transferase that speciﬁcally dimethylates ‘Lys-20’ of histone H4.
Due to the functional importance of this gene and its known
association with breast cancer26,27, we followed this gene
mutation and performed high-depth (sequencing depth
410,000 reads) targeted mutational screening from samples at
the MDS stage (TP1 and TP2). Unlike del(7q), this mutation was
not detected in any of the previous MDS samples (Fig. 6f).
Furthermore, mutational analysis of the HSC, MLP and GMP
compartments (AML stage) revealed that SF3B1 and DNMT3A
mutations were present in all the compartments. However,
SUV420H1 mutation was not detected in HSCs but originated
from MLPs and propagated to GMPs, supporting the hypothesis
of mutations acquired at a MDS progenitor stage conferring self-
renewal ability (Fig. 6g; Supplementary Fig. 8C). Taken together,
our data suggest that SF3B1 mutation precedes del(7q)
aberration and is maintained throughout the disease evolution
(Fig. 6h). Furthermore, acquisition of additional ‘potent’
mutations such as SUV420H1 in the ‘SF3B1-del(7q)’ subclone
in the MLP compartment led to the expansion of this MLP
clone and hence transformation to AML (Fig. 7). Overall, our
results provide evidence for the existence of MDS-ICs in the
MDS-RS disease, which persist during the AML transformation
and could potentially provide a reservoir of the pre-leukaemic
stem cell, as well as play an important role during disease
relapse.
Discussion
Next-generation sequencing technologies have greatly improved
our understanding of the genetic landscape in cancer. Previous
work in AML and MDS demonstrated the existence of clonal
heterogeneity that evolves upon disease progression and/or
relapse14,28–31. To date, various studies including ours have
shown that SF3B1 is the most frequently mutated gene in MDS
with a remarkably strong association with a speciﬁc disease
phenotype, that is, the presence of ring sideroblasts3–5, suggesting
that this mutation is casually linked to event-deﬁning ring
sideroblastic anaemia. However, it is noteworthy that studies so
far have not determined the origins of SF3B1 mutations within
the haematopoietic compartment and the composition of the
SF3B1 subclones. Similarly, the functional heterogeneity of
genetically deﬁned SF3B1 mutant subclones has not been
delineated. SF3B1 mutations are detected in low-risk disease
and therefore, these patients in general have low frequency of
other gene mutations4,8,20. However, the recurrent gene
mutations that coexist with SF3B1-mutated patients are TET2,
DNMT3A and JAK2. In fact, based on previous data, TET2 (26%)
and DNMT3A (21%) occur roughly at the same frequency in the
SF3B1 mutant patients, whereas mutations such as ASXL1 coexist
only in 8% of the SF3B1-mutated patients (Supplementary
Table 3). Here we used WES, capture-based targeted high-
depth sequencing, long-term culture assay, xenotransplantation
as well as single-cell clonogenic assays to study the characteristics
of SF3B1 mutant haematopoietic cells. Mutational analysis
of the SF3B1 gene in haematopoietic stem/progenitor cells
reveals that SF3B1 mutations arising in phenotypically deﬁned
CD34þCD38CD45RACD90þCD49fþ stem cells therefore
unveil the MDS-ICs existence in RARS that propagate mutations
to their myeloid progenitors, such as MPPs, GMPs and MEPs.
This was also reﬂected in clonogenic assays where SF3B1
mutations were detected either alone or in combination with
other mutations in individual CFC colonies, therefore implying
that SF3B1 aberrations precede other gene mutations. Similar
results have been described recently, in MDS patients with
concurrent SF3B1 and del(5q) aberrations, where SF3B1
mutations were shown to be present in CD34þCD38CD90þ
stem cells in these patients15.
In our study, xenotransplantation of CD34þ BM from MDS
samples in immunodeﬁcient mice demonstrated the persistent
long-term myeloid-restricted engraftment in the majority of
cases. In contrast, NSG data from one congenital sideroblastic
anaemia patient carrying an ALAS2 mutation and other healthy
donors showed a multi-lineage engraftment with high a
percentage of the lymphoid/myeloid cell ratio. It is noteworthy
that all four patients in our study had only one common genomic
aberration, that is, SF3B1. In addition, 2/4 patients (MDS2 and
MDS3) had a lower mutation rate (2–4 mutations per exome),
which is less as compared with that in AML (E13), chronic
lymphocytic leukaemia (E12), and was signiﬁcantly lower as
compared with multiple myeloma (E33), hence representing a
much more homogenous clonal population.
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Figure 6 | Clonal evolution from MDS to AML in RCMD-RS patient with SF3B1 mutation. (a) FACS proﬁles of stem cell progenitors in BM MNCs in a
serial sample at the MDS stage and AML stage of the disease. (b) Interphase FISH for tracking the del(7q) aberration in cells obtained at the AML stage of
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for HSCs was410,000 reads. (h) Proposed sequential acquisition of genetic lesions based on analysis of sequential samples, LTC-derived cells and single-
cell clonogenic assays.
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Notably, the genotypic analysis of pre- and post-transplanted
cells demonstrate that in most of the cases SF3B1 mutations were
maintained; however, in one case (MDS3), SF3B1 mutant clone
increased from 27% in primary CD34þ cells to 47% in HEC
samples. This suggests the presence of a mixed stem cell
population (that is, SF3B1 mutant/wild type), which when
injected into immunodeﬁcient mice resulted in the expansion of
SF3B1 mutant clones preferentially. Exclusive myeloid engraft-
ment and the maintenance/increase in the SF3B1 clone(s) in NSG
xenografts suggest that a malignant HSC clone with SF3B1
mutations either alone or in conjunction with other ‘cooperating
factors’ has a growth advantage or a negative feedback over the
cohabitating normal HSC.
Interestingly, in all mice that have detectable human engrafted
cells, we could see a similar subclonal architecture compared with
MDS cells injected. Nevertheless, in some cases, the engrafting
SF3B1 daughter subclones represented only a small fraction of the
injected cells (o5%), implying that some SF3B1 subclones have a
cell-intrinsic advantage (due to better engraftment ability,
enhanced proliferation potential and/or additional factors)
following xenotransplantation. Malignant clones with ‘isolated
SF3B1’ mutations are not always driven away by more ‘potent’
mutant subclones (such as DNMT3A and/or JAK2) in NSG mice
as was reﬂected by its MAB, which remained stable even though
other subclones were ﬂuctuating. Perhaps additional driver
mutations when acquired by the SF3B1 clones confer a subtle
advantage to the new daughter subclone representative of early
stages in disease progression, as evidenced in MDS1 (time point 1
versus time point 2). However, when these clones acquire more
aggressive mutation(s), as is the case here for MDS2, a more
‘aggressive’ mature progenitor clone with self-renewing capacity
is generated, enabling the disease to evolve into AML. It is
tempting to speculate that SUV420H1 mutations confer a growth
advantage based on the evidence that Suv420h (referred to both
Suv420h1 and Suv420h2)-deﬁcient MEFs and ES cells have been
reported to have telomere elongation and epigenetic defects32.
Further work needs to be done to study the role of SUV420H1
mutation(s) in haematological diseases.
It is noteworthy that a small subclone with SF3B1 mutation
harbouring del(7q36) becomes a predominant clone in the
sequential AML sample (MDS2), but with the additional
acquisition of del(7q22). Therefore, SF3B1 mutation in isolation
might only have a minor role in disease transformation or
progression to AML. However, similar to del(5q) aberrations15, it
may instead be a strong driver mutation in MDS-RS and acquires
additional mutations during the course of the disease progression.
Previous studies of functional heterogeneity in human
leukaemias have used NSG mice to characterize leukaemia stem
cells to decipher their engraftment potential, self-renewal
capacity33–36. Nevertheless, Tim Ley’s group was the ﬁrst to
report functional heterogeneity of genetically deﬁned subclones in
AML14. Their data suggested that xenotransplantation results in a
marked decrease in the subclonal complexity of the AML samples
and were not able to reliably predict disease relapse. However, the
combination of our WES in xenotransplanted NSG mice and
serial patient sampling enabled us to compare the clonal
evolution observed in mice with that of patient BM
compartment in MDS1 and MDS2. The changes in the
spectrum of SF3B1 mutant clones observed in the NSG mice
were largely reﬂected in the patient’s sequential BM cells where
similar clonal changes were detected, although the SF3B1 clonal
ﬂuctuation observed in NSG mice for MDS1 was more
remarkable as compared with MDS2.
This study demonstrates that SF3B1 mutations can originate in
rare CD34þCD38CD90þCD49fþ HSCs, and MDS-ICs are
restricted to these rare HSC fractions in our cohort of MDS
patients with ring sideroblasts. Although our data are limited to
ﬁve patients, the presence of SF3B1 mutations in CD34þCD38
CD90þCD45RACD49fþ HSCs provides new insight into
the MDS stem cells. Furthermore, our data demonstrate that
SF3B1 mutations could act as an initiating event in MDS-RS
disease, as has been suggested by previous studies3,5. We could
not, nevertheless, exclude that in other RARS cases, mutations
such as TET2 and ASXL1 (not studied here) could also act as
initiating mutations. Further analysis of a larger cohort of
patients, using single-cell or the clonogenic assay should address
this point.
MDS2 patient progression to AML illustrates the concept of a
switch from ‘HSC disease’ to a ‘progenitor disease’. Here, we show
that in some cases MDS-RS can originate from the stem cells and
at a later stage of the disease de novo mutation(s) acquired by the
progenitor cells can confer the self-renewal capability to the MDS
progenitor cells that drives leukaemic transformation. This novel
observation conﬁrming the presence of MDS-IC at the AML stage
provides new insight into the MDS/AML hierarchy. Our results
also suggest that MDS-IC at the AML stage can constitute a pool
of pre-leukaemic cells, providing a reservoir of cells that could be
responsible for relapse. Although mutations such as SF3B1 are
not driving mutations at the AML stage, they provide a genuine
target for curative therapies and give the opportunity to
therapeutically target at the same time the AML blasts as well
as pre-leukaemic cells.
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Figure 7 | Predicted model for sequential acquisition of genetic lesions in MDS to AML transformation. SF3B1 mutations are acquired in
CD34þCD38CD90þCD45RACD49fþ HSCs. As HSCs replenish downstream progenitors, mutations acquired in stem cells are also propagated to
mature progenitors but without conferring self-renewal potential. However, as the mature progenitors such as MLPs harbouring a mutant SF3B1 acquires a
more ‘potent hit’ such as SUV420H1 mutation, they confer self-renewal potential and suppress the HSC to MPP transition.
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Methods
Patients. WES data were available for 12 MDS-RS patients (Supplementary
Table 1) and one congenital sideroblastic anaemia patient. In addition, one MDS-
RS patient with SF3B1 mutation was also included in this study. All patient samples
(n¼ 14) were received from the King’s College London Haemato-Oncology Tissue
Bank. All patients had provided written informed consent for the samples to be
used for all the experiments in accordance to the King’s College London Haemato-
Oncology Tissue Bank research ethics protocol (08/H0906/94). Demographic and
clinical characteristics of the studied patients are detailed in Supplementary
Table 1. All patients were risk stratiﬁed according to IPSS categories. The clinical
variables for all patients were ascertained at the time of sample collection.
Sequential (post AML transformation) samples from MDS2 was also available
(Supplementary Tables 1 and 4).
BM aspirates from 6/12 MDS-RS (MDS1, MDS2, MDS3, MDS4, MDS6 and
MDS14) all containing the SF3B1 mutations (K700E, n¼ 2; H662Q, n¼ 3) and one
congenital sideroblastic anaemia patient (MDS5, wild-type SF3B1) were selected for
in vivo, in vitro experiments and/or haematopoietic cell separation (Supplementary
Tables 1 and 4).
Xenotransplant assays. MNCs were isolated from the BM cells by centrifugation
using Ficoll-Paque PLUS (GE Healthcare Life Sciences, Buckinghamshire, UK).
The cells were processed within 24 h following collection using an Easysep Human
CD34-positive selection kit and Easysep magnet (StemCell Technologies, Van-
couver, Canada) according to the manufacturer’s instructions to enrich CD34þ
cells from patient samples. Mesenchymal stem cells were isolated from the CD34
fraction during the CD34þ cell selection. Cells were seeded at a concentration of
1.106/cm2, in DMEM low glucose (Life Technologies, Paisley, UK) supplemented
with fetal bovine serum (Mesenchymal Stem Cell Qualiﬁed, Life Technologies).
Culture media was replaced 3 days later, and cells were frozen at passage-2
maximum.
NSG mice were a kind gift of Dr Leonard Shultz (The Jackson Laboratory). All
animal experiments were performed in accordance to Home Ofﬁce and CRUK
guidelines. Female NSG mice used in this study were 8 to 12 weeks old at the start
of the experiments. Before transplantation, mice received a sub-lethal dose of
radiation (375 cGy) from a caesium-137 source. Direct intra-BM injection was
performed in the tibia with 0.65 105 to 2 105 BM CD34þ cells from patients
and healthy donors.
Engraftment was assessed over time by intra-tibia aspiration under isoﬂurane
anaesthesia, and the BM was immunophenotyped by the presence of mCD45 ,
hCD45þ , hCD33þ , hCD19 and hCD3 (using anti-mouse and anti-human
antibodies from BD Biosciences, Oxford, UK) cell populations. After 18–20 weeks,
mice experiments were terminated and cells were harvested from pooled BM
(femurs, tibias, pelvis and/or spine). Live cells were stained and sorted on the
hCD45þ phenotype using FACS Aria SORP (BD Biosciences). Sorted cells were
washed in PBS and harvested to later perform genomic analysis.
CD45 Immunohistochemistry. Femurs were collected from engrafted and non-
engrafted mice, washed in PBS, ﬁxed overnight at 4 C in 4% paraformaldehyde
(methanol free). Samples were washed in PBS once before being washed in water.
Bones were incubated 2 h on ice in 8% HCl solution for decalciﬁcation. Samples
were rinsed with water and stored in PBS before immunostaining.
Tissues were ﬁxed in 10% neutral buffered formalin overnight and processed for
parafﬁn embedding and sectioned at 4M. Sections were microwaved for 15min in
0.01M sodium citrate buffer pH 6 for antigen retrieval. Sections were blocked with
1.6% H2O2/PBS and then 10% normal horse serum/1% BSA and stained for 1 h
with mouse anti-CD45 (Dako M0701, Cambridgeshire, UK) at 1/200 dilution.
Secondary antibody was used with biotinylated horse anti-mouse IgG (Vector Labs,
Peterborough, UK), followed by ABC reagent (Vector Labs), developed with DAB
(Vector Labs) and counterstained with haematoxylin. Pictures were taken using an
inverted microscope and analysed with NIS-Elements software from Nikon.
CD45 immunohistochemistry. Femurs were collected from engrafted and non-
engrafted mice, washed in PBS, ﬁxed overnight at 4 C in 4% paraformaldehyde
(methanol free). Samples were washed in PBS once before being washed in water.
Bones were incubated 2 h on ice in 8% HCl solution for decalciﬁcation. Samples
were rinsed with water and stored in PBS before immunostaining.
Tissues were ﬁxed in 10% neutral buffered formalin overnight and processed for
parafﬁn embedding and sectioned at 4M. Sections were microwaved for 15min in
0.01M sodium citrate buffer pH 6 for antigen retrieval. Sections were blocked with
1.6% H2O2/PBS and then 10% normal horse serum/1% BSA and stained for 1 h
with mouse anti-CD45 (Dako M0701) at 1/200 dilution. Secondary antibody was
used with biotinylated horse anti-mouse IgG (Vector Labs), followed by ABC
reagent (Vector Labs), developed with DAB (Vector Labs) and counterstained with
haematoxylin. Pictures were taken using an inverted microscope and analysed with
NIS-Elements software from Nikon.
Isolation of HSCs and progenitors. BM MNCs were separated from total BM
cells by density-gradient sedimentation with Histopaque-1077 (Sigma-Aldrich Co.
LLC). Up to 1 108 MNCs were resuspended in 350 ml of auto-MACS running
buffer and subsequently used for immunomagnetic enrichment of CD34þ cells
using MACS. CD34þ cells were enriched by positive selection as per the manu-
facturer’s instructions (Miltenyi Biotec Ltd, CD34 MicroBead Kit Human). CD34þ
cells were kept on ice for subsequent use and CD34 cells were stored as viable
cells in Synth-A-Freeze media (Life Technologies) at  80 C.
Up to 1 106 CD34þ cells were stained with the following antibodies: 5 ml of
CD45 (APC-eFluor 780, clone HI30), 1 ml of CD49f (FITC, clone GoH3), 5ml of
CD34 (PE-Cy7, clone 4H11), 5 ml of CD38 (APC, clone HIT2), 5 ml CD135 (PE,
clone BV10A4H2) (eBioscience), 5 ml of CD45RA (BV 510,clone HI100), 2 ml of
CD90 (Alexa Fluor 700, clone5E10) (Biolegend UK Ltd) and a lineage-speciﬁc
antibody cocktail (1 ml of CD2 biotin, 1 ml of CD3 biotin, 1 ml of CD14 biotin, 1 ml
of CD16 biotin, 1 ml of CD19 biotin, 1 ml of CD24 biotin, 1 ml of CD56 biotin, 1 ml
of CD235a biotin; together with 5 ml of Streptavidin eFluor 450, all by eBiosciences
and CD66b (V450) (BD Biosciences). Propidium iodide was added to the cell
suspension before sorting to exclude dead cells. Cells were sorted on a BD FACS
Aria SORP (San Jose, CA) operating in a four-way purity sort mode, and collected
into 1.5-ml microfuge tubes. Our cell populations of interest were deﬁned by
hierarchical gating, which was largely similar to the one used by Notta et al.23;
HSCs as LinCD45þCD34þCD38CD45RACD90þCD49fþ , MPPs as
LinCD45þCD34þCD38CD45RACD90CD49f , GMPs as
LinCD45þCD34þCD38þCD135þCD45RAþ and MEPs as LinCD45þ
CD34þCD38þCD135CD45RA (Supplementary Fig. 1). Moreover, in the case
of the AML sample, CD123 antibody (PE, clone: 6H6, eBioscience) was used
instead of CD135 to deﬁne the CMP, MEP and GMP compartments.
After sorting, the purity of MPPs, GMPs and MEPs were checked and a sorting
purity of Z97% was routinely obtained. Cells were spun down after sorting,
supernatant was discarded and cells were either stored at  80 C and/or
resuspended in Karnoy’s solution to later perform FISH analysis.
Whole-genome ampliﬁcation. WGA of cells was performed with the Genome-
Plex Single Cell Whole Genome Ampliﬁcation kit (WGA4, Sigma-Aldrich Co,
LLC) and/or GenomePlex SeqPlex XE kit (SEQXE, Sigma-Aldrich Co., LLC). WGA
ampliﬁcation was performed according to the instructions of the manufacturer,
along with a no-cell reaction as a negative control and a reaction of human tissue
genomic DNA (gDNA) as a positive control.
For patient samples where only one mouse was used in in vivo experiments, two
independent ampliﬁcation experiments were performed using two different
ampliﬁcation kits (that is, WGA4 and SEQXE). In addition, all patients samples,
the HSCs and MPPs were also ampliﬁed by two different ampliﬁcation kits (WGA4
and SEQXE), while the GMPs and MEPs were ampliﬁed by using the SEQXE
WGA kit.
WES and data analysis. Thirteen MDS-RS patients were selected for WES, using
DNA from CD34þ cells (primary BM sample) in all cases and paired constitu-
tional DNA from 11 cases (skin, n¼ 7; CD3þ n¼ 4). One additional MDS-RS
patient was subjected to targeted mutational analysis. The WES data have been
deposited in the NCBI Sequence Read Archive under accession code XXX.
CD45þCD33þ cells derived from mice (human engrafted cells) from four of
these patients (MDS1, MDS2, MDS3 and MDS4) were also subjected to WES. WES
was also performed on three LTC-derived samples from three patients (for more
details, see Supplementary Table 4). For cases where WGA was performed
using two independent WGA kits, both WGA samples were independently
processed for WES.
gDNA (non-WGA, 100–500 ng) or WGA DNA (500 ng) was processed for
exome sequencing (Agilent V4) and sequenced on the Illumina HiSeq2000 (Paired
end V3 chemistry) according to manufacturer’s instructions. Base calling was
generated by the Illumina RTA software. Demultiplexing and conversion of
basecalls to fastq was performed by Casava version 1.8.2, ﬁltering out poor-quality
reads fastq ﬁles concatenated. Alignment, realignment and recalibration was
performed using Burrows–Wheelers aligner37 and GATK38, respectively, according
to the Broad Institute best practices for individual samples. VarScan 1.3.4
(refs 39,40) was subsequently used to call somatic variants on pileup ﬁles
(Samtools)41 for paired tumour and normal (skin or CD3þ T cells) tissue. Reads
with an alignment score ofo10, base quality scoreo15 and fold strand bias410
were excluded. Pindel42 was also used to screen for more computationally
challenging Indel mutations at speciﬁc loci, such as for FLT3 ITD. All resulting
variants were passed through ANNOVAR43 using refseq annotation, and variants
deemed to cause protein changes and not found in dbSNP135, esp5400 and 6500,
and 1,000 genomes databases at 40.001 population allele frequency were passed.
Genomic duplicated regions were also ﬁltered out unless associated with known
mutations. Somatic mutations were subsequently passed when the somatic P value
(VarScan, Fisher’s exact T-test) was o0.01, had Z3 reads supporting mutation,
were present in paired normal skin tissue ato20% (or for paired t-cellso50%) at
o20% of the paired tumour tissue and had an allele burden of 45%. For isolated
HEC CD45þCD33þ cells, candidate mutations were only passed if they were
present in41 HEC sample or found concurrently in one or more HEC experiment
and LTC-derived sample or primary CD34þ cells for the same patient. Where only
WGA-derived data from HEC were available for one engraftment experiment, or a
combination of WGA and non-WGA data from more than one engraftment
experiment, mutations were only passed when they were found concurrently in
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either: (1) WGA HEC and non-WGA HEC-independent experiments; (2) repeat
WGA DNA samples from the same engraftment experiments or; (3) WGA HEC
experiments and LTC-derived sample, CD34þ or HEC experiments derived from
non-WGA DNA. For WGA-derived HEC, a stand-alone analysis was also
performed for individual experiments. For this, additional false-positive ﬁlters were
applied to remove additional WGA-derived artefacts with positional and read-
length distribution bias, as well as variant and mapping quality biases. Variants
with homopolymer runs of ﬁve or more ﬂanking the mutation were also ﬁltered
out. WGA-derived variants from control WGA experiments were also removed.
For MDS3, only variants found in at least two of the three animal experiments
from WGA-derived data were included in the ﬁnal list due to increased artefactual
events. Stand-alone analysis of non-WGA HEC cells were likewise performed but
only using ﬁlters up to step 7 above.
Mapping loss of heterozygozity across chromosomes by WES. Loss of het-
erozygosity was mapped from WES data according to the following criteria: var-
iants were called as described above. Variants found in the 1,000 genome project
database with a population allele frequency o0.001 were selected and ﬁltered out
for known genomic duplicated regions, read depth o20 and somatic status
according to VarScan. The ﬁltered set of variants was then plotted graphically for
the required chromosome.
Exome coverage. Exome coverage was calculated utilizing GATK Depth Of
Coverage script against intervals that the Agilent V4 Sureselect kit capture probes
were based on. For non-WGA sample, mean base coverage across the targeted
region ranged from  77 to 115 and for 498% of the exome base coverage was
410 reads in all cases, based on 9–13 gigabase of sequence data. For the same
amount of sequence data on average, WGA-derived exome data yielded an average
base coverage of  55–75 and 65–83% (average 74%) of exome coveredZ10 reads.
Sequencing validation experiments. All somatic mutations were conﬁrmed
independently by sequencing from three independent PCR reactions from all
experiments (CD34þ day-0 samples, HEC from mice, LTC and CFC), which
enabled us to quantify the MAB more accurately in all cases.
Primers for candidate gene variants were designed by using Primer 3 program44
with default settings. Using relevant candidate gene-speciﬁc primers and GoTaq
Hot Start Colorless Master Mix (Promega), PCR ampliﬁcation was performed on
all primary CD34þ samples, HEC samples, LTC-derived cells and pooled CFC by
following manufacturer’s protocol. The acquired nature of the mutations was also
conﬁrmed by their absence in paired constitutional DNA. In the case of WGA-
derived candidate mutations, validation was also conﬁrmed in at least one gDNA
(non-WGA) sample from that particular patient.
In the case of WGA-derived candidate mutations, validation was also conﬁrmed
in at least one gDNA (non-WGA) sample from that particular patient. The degree
of quantitative accuracy of the allele burdens for WGA DNA was validated by
performing WES on paired gDNA (non-WGA) and WGA DNA from the samples
(Supplementary Fig. 3). For this, we observed a similar distribution of known
single-nucleotide polymorphisms across the exome between the gDNA (non-
WGA) and WGA DNA. To validate this further, we also performed mutational
screening for 10 genes on paired gDNA (non-WGA) and WGA DNA from two
(MDS1 and MDS2) independent patients (Supplementary Fig. 3). MAB for speciﬁc
mutations was also shown to be comparable between gDNA (non-WGA) and
WGA DNA in targeted amplicon sequencing in these control experiment.
For MDS1, all the mutations including SF3B1 were conﬁrmed in all mice
experiments using gDNA (non-WGA) DNA. In addition, all mutations were also
conﬁrmed in LTC (non-WGA) and CFC (non-WGA) samples. For MDS2, all the
mutations were conﬁrmed in ampliﬁed DNA from mice; however, SF3B1 and four
of the additional mutations were conﬁrmed on gDNA (non-WGA) from mice. In
addition, all mutations were also conﬁrmed in LTC (non-WGA) and CFC (non-
WGA) samples. For MDS3, all the mutations including SF3B1 identiﬁed in two
animals from ampliﬁed DNA were also found in one gDNA (non-WGA) from
mice. In addition, all mutations were also conﬁrmed in LTC (non-WGA) and CFC
(non-WGA) samples. For MDS4, SF3B1 and one additional mutation was
conﬁrmed in mouse gDNA (non-WGA).
Furthermore, all somatic mutations were conﬁrmed independently by
sequencing from three independent PCR reactions from all mice experiments,
which enabled us to quantify the MAB more accurately in all cases. The degree of
quantitative accuracy of the allele burdens for WGA DNA was validated by
performing WES on paired gDNA (non-WGA) and WGA DNA from the samples
(Supplementary Fig. 2). For this, we observed a similar distribution of known
single-nucleotide polymorphisms across the exome between the gDNA (non-
WGA) and WGA DNA. To validate this further, we also performed mutational
screening for 10 genes on paired gDNA (non-WGA) and WGA DNA from 2
(MDS1 and MDS2) independent patients (Supplementary Fig. 2). MAB for speciﬁc
mutations was also shown to be comparable between gDNA (non-WGA) and
WGA DNA in targeted amplicon sequencing in these control experiments.
Here, PCR amplicons were normalized, mixed in batches and converted into
Illumina sequencing libraries utilizing transposon-based Illumina-Nextera
technology (Illumina), designated nextera-amplicon libraries here. These libraries
were sequenced on the Illumina MiSeq utilizing version 2 chemistry, 150–250
paired-end reads and dual indexes allowing multiplexing of 96 samples independent
of sequencing experiments utilizing the nextera-amplicon methodology.
Primers used for validation. Target genes oligo sequence (50 to 30)
SF3B1_14f CCAACTCATGACTGTCCTTTCTT
SF3B1_14r GGGCAACATAGTAAGACCCTGT
SF3B1_15f TTGGGGCATAGTTAAAACCTG
SF3B1_15r TTCAAGAAAGCAGCCAAACC
JAK2_E14f TCCTCATCTATAGTCATGCTGAAA
JAK2_E14r CTGACACCTAGCTGTGATCCTG
DNMT3A_E8r TCTTGCCTCATTCAGATGGA
DNMT3A_E8r CCTGGGATCAAGAACCTTCC
DNMT3A_E15f ACCAGGGCTGAGAGTCTCCT
DNMT3A_E15r AGGCTCCTAGACCCACACAC
FBLIM1_f CGAGAAGGGTTTGTGCACTG
FBLIM1_r TCCCAGGTTCACGCCATT
HIST1H2AC_f CGCGACAACAAGAAGACTCG
HIST1H2AC_r GCAGTGAGGTTAGCTCTTCC
HSPA12A_f CCAGTGTGCCCTCAAAAGTC
HSPA12A_r CTTATGCAGTTCGGGGACAC
RETNLB_f AAGAATGGGCAAGGGGTCTC
RETNLB_r ATGGGGAGGATAGCTCATGG
SMC6_f TGGAACATTAGGGCCAAATCT
SMC6_r GCCAAGTTTTGAGGACTCCA
SP3_f AGCCAGACTGACTTGTTCTTTG
SP3_r CTGGAGAACGCCCTTTTGTT
TH_f CACGGATGTGTAGCAAAACG
TH_r CCTGCTTTTGCTCCCTAAGA
NAGA_f CGTAGTCAGCCAGGAAAGGA
NAGA_r GCTCAGCAAGGTCATGGTTT
NMNAT2_f CTCTCTCACTCCTCCAGCTG
NMNAT2_r TGTGGAAGAATGGAAGCGGA
NR0B2_f GCAAAAGCATGTCCCCAAGA
NR0B2_r CAGTCTTGTCCTTTGGTGGC
SPATA13_f CGCCGTGTGTGAGATTCTC
SPATA13_r CAGCCTCAGTCACATTGCTC
TLL2_f CCCCTCAATACAGTCCCCAA
TLL2_r AGGCTCTATTGCTCCTGGTG
G3BP1_f AGTCAGTGCCATGATTTTACCA
G3BP1_r ACAATGCAAGTTCTTATGCAGC
ABCB11_f AACAGACCAGCACTCACCTT
ABCB11_r TCATAAAACAGAGCAACAACCAG
CCDC17_f CTTTCCAGAACTGCTCAGCG
CCDC17_r GAGACCCGACTAAGCGGATC
ME1_f TACCTTGGCTTCCGAAACAC
ME1_r ACAGGCATGAACCACTGTGC
CAMTA1_f GTTCTCTGCAGGGAGGAGTG
CAMTA1_r CTGCCCTAAATCGTGCTCTC
PTPDC1_f CGCAAATTAGAGGATCACAACA
PTPDC1_r CCCTTCCTCCAGAAATGTGT
MYH14_f AAGACCCGGATATGGGAAGT
MYH14_r TCCTCCCTCAACAGATCCAC
Colony-forming cell. Five hundred cells from the BM CD34þ -enriched fraction
were plated in triplicate in 0.5ml of MethoCult H4434 (StemCell Technologies). At
day 14 of culture, the numbers of colonies were scored. Single-cell colony images
were acquired with a Zeiss AxioVert 40 CFL microscope using  5 lens and
connected to Canon PowerShot A640 digital camera. Cells were picked, harvested
and washed twice with PBS. All CFC colonies were screened for SF3B1 and
additional patient-speciﬁc mutations.
LTC assay. LTC assays were performed by plating 103 CD34þ BM cells in
quadruplets on irradiated MS-5 murine stromal cells and cultured in Myelocult
H5100 (StemCell Technologies) in the presence of cytokines (20 ngml 1 G-CSF,
20 ngml 1 IL-3 and 20 ngml 1 TPO from PeproTech, London, UK). After 5
weeks, live cells were stained and sorted on the human CD45þ phenotype using
the FACS Aria SORP (BD Biosciences). Sorted cells were washed in PBS, harvested
and stored as cell pellet and/or resuspended in Karnoy’s solution to later perform
FISH and sequencing analysis.
Genotyping of single-cell clones and/or colonies. CFU-GM and BFU-E colo-
nies were harvested for four patients (MDS1, MDS2, MDS3 and MDS4) at day 14,
and washed twice with PBS. All colonies were subjected to WGA (single-cell WGA,
Sigma-Aldrich). All CFC colonies were screened for SF3B1 and additional patient-
speciﬁc point mutations. Amplicon libraries were ampliﬁed through PCR using the
primers speciﬁc to gene mutations and subjected to Nextra-Illumina sequencing.
Gene mutation for each single colony was called when 430% of the sequencing
reads were carrying a mutant allele.
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Amplicon sequencing for cell fractions. WGA-derived DNA from cell fractions
(HSCs, MPPs, GMPs and MEPs) were subjected to sequencing. Candidate gene
mutations from the WES data were followed-up speciﬁcally. These mutations were
also screened in mesenchymal stem cells (n¼ 4) derived from the concurrent
patients. Furthermore, all somatic mutations were conﬁrmed independently by
sequencing fromZ2 independent PCR reactions. Sequencing was performed using
Nextra Technology (Illumina) and MiSeq platform (Illumina) as described
previously.
MAB is presented as an average of at least two independent Illumina-Nextera
validation experiments combined with data from exome sequencing where
available. In this way, the variation expected from sampling error when working
with small progenitor cell populations was minimized. The average sequencing
coverage across all amplicons was Z800 . This coverage enabled us to reliably
detect mutant clones down to Z1% MAB, deﬁned as the proportion of sequence
reads containing the mutation.
SF3B1 gene mutation were analysed in haematopoietic cell fractions (HSCs,
MPPs, GMPs and MEPs) by PCRs directly on 30–50% of the cell fraction with
subsequent sequencing. For one additional patient (MDS6), which was not used for
in vivo and in vitro experiments, SF3B1 mutation status was assessed in cell
fractions in the same manner.
Fluorescence in situ hybridization. Cells were pelleted, washed twice in PBS and
then resuspended in 0.5 to 1ml of Karnoy’s solution (3:1 methanol/acetic acid
glacial, purchased from Sigma-Aldrich and Fisher Chemical, respectively) and then
stored at 4 C before hybridization. For interphase FISH, ﬁxed cells were
centrifuged and an appropriate amount of supernatant was removed. Pelleted cells
were then transferred onto the slides and hybridized with a XL 7q22/7q36
(Metasystems) locus-speciﬁc probe, which detects deletions in the long arm of
chromosome 7 (Supplementary Fig. 6). The orange-labelled probe targets a speciﬁc
region at 7q22 and the green-labelled probe binds speciﬁcally to 7q36. In addition,
a blue (aqua)-labelled probe, which hybridizes to the centromere of chromosome 7
functions as a reference probe. Fluorescence images were obtained with the help of
ﬂuorescence microscopy. In all, 200–600 interphase cells were analysed per sample.
Statistical analysis. Prism Version 6 software (GraphPad) was used for statistical
analysis. Data are presented as the mean±s.e.m. Statistical analysis was performed
using the two-tailed Student’s t-test for comparison of two groups to determine the
level of signiﬁcance.
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